Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
Public ClinicalTrials.gov record NCT01531153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use. Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention during the first four weeks of treatment will mediate galantamine's efficacy in reducing cocaine use.
Study identification
- NCT ID
- NCT01531153
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2011
- Primary completion
- May 31, 2016
- Completion
- May 31, 2016
- Last update posted
- Oct 25, 2018
2011 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Department of Veterans Affairs | West Haven | Connecticut | 06516 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Addiction trials
Other public records listing Addiction. Sorted by last update posted; newest first. Not a recommendation.
- NCT07740291: Tirzepatide Impact Assessment Study Recruiting
- NCT07585006: Comparative Evaluation of Nicotine Analogs Not yet recruiting
- NCT06015893: Semaglutide Therapy for Alcohol Reduction (STAR) Recruiting
- NCT02108054: Behavioral and Functional Task Development, Implementation, and Testing Recruiting
- NCT07340554: Neuroimaging of Adolescent Cannabis Use Treatment Recruiting
- NCT06624137: Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01531153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2018 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01531153 live on ClinicalTrials.gov.